title: Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: a 5-year study.
abstract: BACKGROUND
  Antiretroviral treatments (ART) form the basis of adequate clinical control in human immunodeficiency virus-infected patients, and adherence plays a primary role in the grade and duration of the antiviral response. The objectives of this study are: (1) to determine the impact of the implementation of a pharmaceutical care program on improvement of ART adherence and on the immunovirological response of the patients; and (2) to detect possible correlations between different adherence evaluation measurements.
  
  
  METHODS
  A 60-month long retrospective study was conducted. Adherence measures used were: therapeutic drug monitoring, a simplified medication adherence questionnaire, and antiretroviral dispensation records (DR). The number of interviews and interventions related to adherence made for each patient in yearly periods was related to the changes in the adherence variable (measured with DR) in these same yearly periods. The dates when the laboratory tests were drawn were grouped according to proximity with the study assessment periods (February-May, 2005-2010).
  
  
  RESULTS
  A total of 528 patients were included in the study. A significant relationship was observed between the simplified medication adherence questionnaire and DR over the 60-month study period (P < 0.01). Improvement was observed in the mean adherence level (P < 0.001), and there was a considerable decrease in the percentage of patients with CD4+ lymphocytes less than 200 cells/mm(3) (P < 0.001). A relationship was found between the number of patients with optimum adherence levels and the time that plasma viral load remained undetected. The number of interviews and interventions performed in each patient in the first 12 months from the onset of the pharmaceutical care program (month 6), was related to a significant increase in adherence during this same time period.
  
  
  CONCLUSIONS
  The results suggest that the establishment and permanence of a pharmaceutical care program may increase ART adherence, increase permanence time of the patient with undetectable plasma viral loads, and improve patients' lymphocyte count.
authors: Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain.
authors: María Jesús
authors: MJ
authors: Hernández Arroyo
authors: Salvador Enrique
authors: SE
authors: Cabrera Figueroa
authors: Rosa
authors: R
authors: Sepúlveda Correa
authors: María de la Paz
authors: Mde L
authors: Valverde Merino
authors: Alicia
authors: A
authors: Iglesias Gómez
authors: Alfonso
authors: A
authors: Domínguez-Gil Hurlé
keywords: CD4+ lymphocyte count; HIV/AIDS; adherence measures; antiretroviral treatment adherence; pharmaceutical care; undetectable PVLs
references: HIV Med. 2008 Feb;9(2):65-71
references: 18257769
references: J Assoc Nurses AIDS Care. 2010 Mar-Apr;21(2):162-72
references: 19804994
references: Clin Pharmacokinet. 2005;44(10):1035-50
references: 16176117
references: Clin Infect Dis. 2011 Nov;53(9):936-43
references: 21890753
references: Can J Hosp Pharm. 2009 Nov;62(6):500-9
references: 22478939
references: HIV Med. 2005 Sep;6(5):366-9
references: 16156886
references: Int J STD AIDS. 2004 Dec;15(12):803-10
references: 15601486
references: J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S158-62
references: 12562042
references: AIDS Behav. 2007 Mar;11(2):161-73
references: 16804749
references: Clin Infect Dis. 2001 Oct 15;33(8):1417-23
references: 11550118
references: AIDS Care. 2010 Oct;22(10):1189-94
references: 20640958
references: Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103
references: 21388714
references: HIV Clin Trials. 2008 Jul-Aug;9(4):238-46
references: 18753118
references: Clin Infect Dis. 2006 Oct 1;43(7):939-41
references: 16941380
references: BMC Health Serv Res. 2008 Nov 20;8:241
references: 19021908
references: AIDS Care. 2000 Aug;12(4):387-98
references: 11091771
references: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001442
references: 16855968
references: Enferm Infecc Microbiol Clin. 2002 Dec;20(10):481-3
references: 12433348
references: BMC Health Serv Res. 2010 Feb 19;10:43
references: 20170479
references: AIDS Care. 2012;24(7):828-35
references: 22272732
references: J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S23-35
references: 17133201
references: J Acquir Immune Defic Syndr. 2002 May 1;30(1):105-10
references: 12048370
references: J Antimicrob Chemother. 2006 Jul;58(1):147-53
references: 16687458
references: AIDS. 2002 Jan 25;16(2):269-77
references: 11807312
references: AIDS Patient Care STDS. 2007 Feb;21(2):92-9
references: 17328658
references: HIV Clin Trials. 2007 Sep-Oct;8(5):282-92
references: 17956829
references: Biol Pharm Bull. 2010;33(8):1426-9
references: 20686242
references: J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):211-8
references: 12794557
references: J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):435-40
references: 12640203
references: AIDS. 2001 Jun 15;15(9):1181-3
references: 11416722
references: J Infect Dis. 2010 Sep 1;202(5):717-22
references: 20662624
references: AIDS Res Hum Retroviruses. 2007 Oct;23(10):1166-75
references: 17961100
references: Enferm Infecc Microbiol Clin. 2000 Jan;18(1):27-39
references: 10721560
references: J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):574-80
references: 18193499
references: Farm Hosp. 2006 May-Jun;30(3):171-6
references: 16999564
references: Curr HIV/AIDS Rep. 2010 Feb;7(1):44-51
references: 20425057
references: Pharmacotherapy. 2006 Aug;26(8):1060-8
references: 16863482
references: Patient Prefer Adherence. 2012;6:457-63
references: 22791983
references: AIDS Behav. 2006 May;10(3):227-45
references: 16783535
references: PLoS Med. 2008 May 20;5(5):e109
references: 18494555
references: AIDS Behav. 2011 Jul;15(5):885-96
references: 21165692
references: Farm Hosp. 2004;28(6 Suppl 1):19-26
references: 15649112
references: J Gen Intern Med. 2004 Nov;19(11):1096-103
references: 15566438
references: PLoS One. 2010 May 05;5(5):e10460
references: 20485480
references: AIDS. 2002 Mar 8;16(4):605-13
references: 11873004
references: Ann Intern Med. 2000 Jul 4;133(1):21-30
references: 10877736
references: Clin Infect Dis. 2001 Aug 1;33(3):386-92
references: 11438909
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 15;810(1):25-34
references: 15358304
references: J Chromatogr B Biomed Sci Appl. 2000 Jul 21;744(2):227-40
references: 10993510
references: J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):123-8
references: 10935687
references: Gac Sanit. 2011 Jul-Aug;25(4):282-9
references: 21546132
references: Farm Hosp. 2008 Nov-Dec;32(6):349-57
references: 19232221
references: MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):250-2
references: 6265753
references: AIDS Res Hum Retroviruses. 2009 Aug;25(8):783-93
references: 19619008
references: Braz J Med Biol Res. 2002 Oct;35(10):1173-81
references: 12424490
references: AIDS Patient Care STDS. 2006 Jul;20(7):511-24
references: 16839250
references: Pharmacogenet Genomics. 2010 Apr;20(4):217-30
references: 20139798
references: AIDS. 2008 Nov 12;22(17):2371-80
references: 18981777